Avanafil - CAS 330784-47-9
Catalog number: 330784-47-9
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C23H26ClN7O3
Molecular Weight:
483.95064
COA:
Inquire
Targets:
Phosphodiesterase (PDE)
Description:
A phosphodiesterase (PDE5) inhibitor, used to treat erectile dysfunction.
Purity:
0.99
Synonyms:
TA-1790; TA 1790; TA1790; Avanafil; trade name: Stendra; Spedra
MSDS:
Inquire
InChIKey:
WEAJZXNPAWBCOA-INIZCTEOSA-N
InChI:
InChI=1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1
Canonical SMILES:
COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCCC4CO)Cl
1.A novel liquid chromatographic method with fluorescence detection for quantitation of tadalafil and dapoxetine hydrochloride in pharmaceutical dosage form and human plasma.
Maha H, Amira K, Mohamed A, Ahmed Emad el G. Se Pu. 2015 Jul;33(7):765-70.
Tadalafil (TAD) and dapoxetine HCl (DAP) are recently co-formulated and both show native fluorescence. Therefore, a novel, accurate, specific and sensitive reversed-phase high performance liquid chromatographic method with fluorescence detection was developed and validated for their separation and quantitation in dosage form and human plasma using avanafil as an internal standard (IS). Separation was achieved using isocratic elution within 7.0 min on C18 column and acetonitrile-0.15% triethylamine (40:60, v/v; pH 4) as a mobile phase. The flow rate was 1.0 mL/min and the detection was time-programmed at 330, 410 and 370 nm for TAD, DAP and IS, respectively, after excitation at 236 nm. The linear ranges from 0.01 to 30.00 μg/mL for each drug with the limits of detection of 4.20 and 7.20 ng/mL for TAD and DAP, respectively. The method was validated in accordance to the International Conference on Harmonization (ICH) guidelines and was successfully applied to spiked human plasma with mean recoveries of 98.
2.The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Ventimiglia E1,2, Capogrosso P1,2, Montorsi F1,2, Salonia A1,2. Expert Opin Drug Saf. 2016 Feb;15(2):141-52. doi: 10.1517/14740338.2016.1131818. Epub 2016 Jan 9.
INTRODUCTION: Phosphodiesterase type 5 inhibitors (PDE5Is) are the leading drugs for the treatment of erectile dysfunction (ED), being recommended as a first line treatment by both the European and US urological guidelines. PDE5Is are highly effective as compared to placebo, well tolerated and have a very low, though not negligible, rate of severe treatment-related adverse events.
3.A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil.
Evans JD1, Hill SR1. Patient Prefer Adherence. 2015 Aug 12;9:1159-64. doi: 10.2147/PPA.S56002. eCollection 2015.
BACKGROUND: Numerous pathways can lead to erectile dysfunction (ED) in patients, with some patients having multiple causes. Regardless of the etiology, ED has been successfully treated in many patients with the advent of oral phosphodiesterase-5 inhibitors (PDE5Is). With the release of avanafil, there are currently four PDE5I options available, and choosing between them should be based on patient-specific considerations and preferences.
4.Current use of phosphodiesterase inhibitors in urology.
Hakky TS, Jain L. Turk J Urol. 2015 Jun;41(2):88-92. doi: 10.5152/tud.2015.46354.
The causes of male erectile dysfunction (ED) are quite variable and are now commonly divided into etiologies such as ischemia, smooth muscle damage, or altered blood flow. Although varying rates of ED have been reported in literature, the number of men with ED is projected to increase worldwide by 2025 to approximately 322 million. Since the introduction of phosphodiesterase 5 (PDE5) inhibitors, there has been a paradigm shift in the treatment of ED because PDE5 inhibitors address a broad spectrum of etiologies for ED. Today, the American Urological Association recommends the use of three PDE5 inhibitors (sildenafil, tadalafil, and vardenafil) as a first-line therapy for the treatment of ED. This review evaluates the pharmacological mechanism of PDE5 inhibitors along with the impact and use of sildenafil, vardenafil, tadalafil, and avanafil. By increasing intracellular cGMP levels, PDE5 inhibitors have been shown to be effective in the treatment of ED.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Phosphodiesterase (PDE) Products


CAS 862189-95-5 Mirodenafil

Mirodenafil
(CAS: 862189-95-5)

Mirodenafil is a newly developed oral phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction. It significantly improved ...

CAS 139145-27-0 Parogrelil

Parogrelil
(CAS: 139145-27-0)

Parogrelil is a selective and potent PDE III (PDE3) inhibitor with bronchodilating and anti-inflammatory activities.

CAS 491-70-3 Luteolin

Luteolin
(CAS: 491-70-3)

Luteolin is a flavonoid found in Terminalia chebula with antioxidant and scavenging activity. It is a non-selective phisphodiesterase PDE inhibitor, and also in...

CAS 189362-06-9 K134

K134
(CAS: 189362-06-9)

K134 is a selective phosphodiesterase 3 (PDE3) inhibitor, and has been shown to exhibit more potent anti-platelet activity than cilostazol. In vivo studies have...

CAS 78416-81-6 Trequinsin hydrochloride

Trequinsin hydrochloride
(CAS: 78416-81-6)

Trequinsin hydrochloride is a highly potent inhibitor of cGMP-inhibited phosphodiesterase (PDE3) (IC50 = 250 pM). Trequinsin stimulates cAMP accumulation at a c...

CAS 37762-06-4 Zaprinast

Zaprinast
(CAS: 37762-06-4)

Zaprinast is a cyclic-GMP phosphodiesterase inhibitor with selectivity for PDE6, 5, 11 and 9 (IC50 = 0.15, 0.76, 12.0 and 29.0 μM, respectively). C-GMP acts as ...

CAS 1160521-50-5 PDE1-IN-1

PDE1-IN-1
(CAS: 1160521-50-5)

PDE1-IN-1 is a potent PDE1 inhibitor and neuroprotective agent.

CAS 81840-15-5 Vesnarinone

Vesnarinone
(CAS: 81840-15-5)

Vesnarinone, a quinolinone derivative, is a cardiotonic agent. It has pharmacodynamic effects include inhibition of phosphodiesterase III (PDE3) activity, incre...

Chemical Structure

CAS 330784-47-9 Avanafil

Quick Inquiry

Verification code

Featured Items